Welcome to our dedicated page for Surrozen news (Ticker: SRZNW), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen, Inc. reports developments tied to its biotechnology business and its public warrant security, SRZNW. Company updates center on targeted therapeutics that use Wnt pathway biology and antibody technologies for sight-threatening ophthalmic diseases, including retinal disease programs such as SZN-8141, SZN-8143 and SZN-413.
Recurring news themes include financial results, business updates, clinical and regulatory disclosures, scientific presentations, research milestones, material agreements, governance changes and capital-structure matters affecting Surrozen common stock and redeemable warrants.
Surrozen, Inc. has completed its business combination with Consonance-HFW Acquisition Corp., a special purpose acquisition company. The merger was approved by shareholders on August 10, 2021, and will enable Surrozen to trade its shares on Nasdaq under the ticker symbol SRZN and its warrants as SRZNW beginning August 12, 2021. Surrozen aims to unlock therapeutic applications of the Wnt pathway for tissue repair and regeneration, with a management team led by CEO Craig Parker, focusing on developing innovative therapies for serious diseases.